# TFF Pharmaceuticals Inc. (TFFP)

Source: https://www.quantisnow.com/company/TFFP
Generated: 2026-11-10T19:31:47.617Z

- Ticker: TFFP
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2019
- Website: tffpharma.com

## About

TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in the Phase I clinical trials used for the prevention of lung transplant rejection. It is also developing other dry powder products, such as Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various types of pain; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.

## Latest TFFP news and filings

- 2025-02-06 21:05 UTC [TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration](https://www.quantisnow.com/insight/tff-pharmaceuticals-announces-delisting-from-nasdaq-and-potential-sec-deregistration-5875465)
- 2024-12-23 11:50 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by TFF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-tff-pharmaceuticals-inc-5823081)
- 2024-12-11 21:05 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by TFF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-tff-pharmaceuticals-inc-5809370)
- 2024-12-10 21:05 UTC [SEC Form 8-K] [TFF Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/tff-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-5807491)
- 2024-11-20 22:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by TFF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-tff-pharmaceuticals-inc-5785358)
- 2024-11-19 21:05 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by TFF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-tff-pharmaceuticals-inc-5782686)
- 2024-11-14 21:20 UTC [SEC Form NT 10-Q filed by TFF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-tff-pharmaceuticals-inc-5776147)
- 2024-11-14 21:15 UTC [SEC Form 8-K] [TFF Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/tff-pharmaceuticals-inc-filed-sec-form-8-k-termination-of-a-5776022)
- 2024-11-14 21:15 UTC [Leadership Update] [TFF Pharmaceuticals Announces It Will Wind Down Operations](https://www.quantisnow.com/insight/tff-pharmaceuticals-announces-it-will-wind-down-operations-5775925)
- 2024-11-14 20:37 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by TFF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-tff-pharmaceuticals-inc-5775167)
- 2024-09-26 11:00 UTC [TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery](https://www.quantisnow.com/insight/tff-pharmaceuticals-technology-generates-superior-inhalational-dry-powder-formulations-for-5705255)
- 2024-09-11 11:00 UTC [TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID](https://www.quantisnow.com/insight/tff-pharmaceuticals-partners-with-emory-university-and-barda-to-develop-5689891)
- 2024-09-10 11:00 UTC [TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization](https://www.quantisnow.com/insight/tff-pharmaceuticals-announces-positive-preclinical-data-from-bivalent-universal-influenza-5688156)
- 2024-09-03 12:00 UTC [Conference Announcement] [TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference](https://www.quantisnow.com/insight/tff-pharmaceuticals-to-present-at-the-hc-wainwright-26th-annual-5679031)
- 2024-08-14 20:05 UTC [SEC Form 8-K] [TFF Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/tff-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-5659034)
- 2024-08-14 20:05 UTC [Public Offering] [TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update](https://www.quantisnow.com/insight/tff-pharmaceuticals-reports-second-quarter-financial-results-and-provides-corporate-5658981)
- 2024-08-14 20:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by TFF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-tff-pharmaceuticals-inc-5658907)
- 2024-08-06 12:00 UTC [SEC Form 8-K] [TFF Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/tff-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5643951)
- 2024-08-06 12:00 UTC [TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection](https://www.quantisnow.com/insight/tff-pharmaceuticals-provides-continued-positive-outcomes-from-tacrolimus-inhalation-powder-5643941)
- 2024-07-08 21:46 UTC [SEC Form 4] [President and CEO Weisman Harlan F was granted 27,480 shares, increasing direct ownership by 3% to 842,095 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-weisman-harlan-f-was-granted-27480-shares-5598002)
- 2024-07-08 21:44 UTC [SEC Form 4] [Director Lee Catherine Chai-Zon was granted 1,583 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-lee-catherine-chai-zon-was-granted-1583-shares-sec-form-5598000)
- 2024-07-08 21:44 UTC [SEC Form 4] [Director Mills Robert S was granted 3,165 shares, increasing direct ownership by 6% to 59,145 units (SEC Form 4)](https://www.quantisnow.com/insight/director-mills-robert-s-was-granted-3165-shares-increasing-direct-5597999)
- 2024-07-08 21:43 UTC [SEC Form 4] [Director Roberts Brandi was granted 3,165 shares, increasing direct ownership by 16% to 23,165 units (SEC Form 4)](https://www.quantisnow.com/insight/director-roberts-brandi-was-granted-3165-shares-increasing-direct-ownership-5597997)
- 2024-07-08 21:43 UTC [SEC Form 4] [Chief Financial Officer Coleman Kirk Allen was granted 10,184 shares, increasing direct ownership by 29% to 45,859 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-coleman-kirk-allen-was-granted-10184-shares-5597996)
- 2024-07-08 21:42 UTC [SEC Form 4] [Chief Medical Officer Mikhak Zamaneh was granted 10,184 shares, increasing direct ownership by 8% to 145,184 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-mikhak-zamaneh-was-granted-10184-shares-increasing-5597995)
- 2024-07-08 21:41 UTC [SEC Form 4] [Director Rocamboli Stephen was granted 3,165 shares, increasing direct ownership by 9% to 39,165 units (SEC Form 4)](https://www.quantisnow.com/insight/director-rocamboli-stephen-was-granted-3165-shares-increasing-direct-ownership-5597994)
- 2024-07-08 21:40 UTC [SEC Form 4] [Director King Thomas Braxton was granted 1,583 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-king-thomas-braxton-was-granted-1583-shares-sec-form-5597991)
- 2024-06-29 00:32 UTC [SEC Form 8-K] [TFF Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/tff-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-5584936)
- 2024-06-26 11:04 UTC [Market Chatter] [TFF Pharmaceuticals Engages Outcome Capital to Explore Partnerships and Licensing](https://www.quantisnow.com/insight/tff-pharmaceuticals-engages-outcome-capital-to-explore-partnerships-and-licensing-5577463)
- 2024-06-26 11:00 UTC [TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities](https://www.quantisnow.com/insight/tff-pharmaceuticals-engages-outcome-capital-as-a-strategic-advisor-for-5577430)
- 2024-06-24 11:10 UTC [Market Chatter] [TFF Pharmaceuticals Announced A Regulatory Update On Its TFF TAC Clinical Program Following Its Recent Interaction With The FDA, Company To Provide More Detailed Regulatory Update In 3Q 2024](https://www.quantisnow.com/insight/tff-pharmaceuticals-announced-a-regulatory-update-on-its-tff-tac-5572279)
- 2024-06-24 11:00 UTC [TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection](https://www.quantisnow.com/insight/tff-pharmaceuticals-provides-regulatory-update-on-tacrolimus-inhalation-powder-tff-5572221)
- 2024-06-14 20:05 UTC [SEC Form S-8] [SEC Form S-8 filed by TFF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-tff-pharmaceuticals-inc-5558999)
- 2024-06-07 21:29 UTC [SEC Form 8-K] [TFF Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/tff-pharmaceuticals-inc-filed-sec-form-8-k-submission-of-matters-5546379)
- 2024-05-23 11:18 UTC [Market Chatter] [TFF Pharmaceuticals And Leidos To Advance Next-Generation Biodefense Countermeasures Under DARPA Personalized Protective Biosystems Program into Preclinical Testing](https://www.quantisnow.com/insight/tff-pharmaceuticals-and-leidos-to-advance-next-generation-biodefense-countermeasures-under-5512037)
- 2024-05-23 11:00 UTC [TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing](https://www.quantisnow.com/insight/tff-pharmaceuticals-and-leidos-to-advance-next-generation-biodefense-countermeasures-under-5511954)
- 2024-05-20 11:05 UTC [Market Chatter] [TFF Pharmaceuticals, Cleveland Clinic Partner To Advance Multiple Multivalent Universal Influenza Vaccines To Protect Against Seasonal, Pandemic Viruses Into Preclinical Testing](https://www.quantisnow.com/insight/tff-pharmaceuticals-cleveland-clinic-partner-to-advance-multiple-multivalent-universal-5502566)
- 2024-05-20 11:00 UTC [TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing](https://www.quantisnow.com/insight/tff-pharmaceuticals-and-cleveland-clinic-to-advance-multivalent-universal-influenza-5502507)
- 2024-05-17 20:19 UTC [Market Chatter] [TFF Pharmaceuticals Entered Into An At Market Offering Agreement With H.C. Wainwright & Co., LLC](https://www.quantisnow.com/insight/tff-pharmaceuticals-entered-into-an-at-market-offering-agreement-with-5500656)
- 2024-05-17 20:07 UTC [SEC Form 424B5] [SEC Form 424B5 filed by TFF Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-tff-pharmaceuticals-inc-5500375)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/TFFP
- Earnings history: https://www.quantisnow.com/earnings/TFFP
- Dividend history: https://www.quantisnow.com/dividends/TFFP
- Insider transactions: https://www.quantisnow.com/insiders/TFFP
- Options chain: https://www.quantisnow.com/options/TFFP
- SEC 8-K filings only: https://www.quantisnow.com/company/TFFP/8-k
- RSS and alerts for TFFP: https://www.quantisnow.com/docs/rss-feeds.md